C73: Malignant neoplasm of thyroid gland
C73 is a billable, specific ICD-10-CM code for malignant neoplasm of thyroid gland. It is valid for submission on a claim.
Check C73 with the rest of the claim: free scrubberUse additional code
Add a secondary code to capture the detail described below.
- code to identify any functional activity
Other codes that can never be billed with C73
Their own Excludes1 notes name this code, so the conflict is not listed above.
- C75Malignant neoplasm of other endocrine glands and related structures
Risk adjustment
C73 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 23 Prostate, Breast, and Other Cancers and Tumors0.186 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score. Look up the whole chart to see which of its HCCs the hierarchy would zero.
Medicare coverage
C73 is named in 69 Medicare coverage policies: 69 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.
- A52370Billing and Coding: Bevacizumab and biosimilars
- A52399Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
Alphabetic index entries that lead here
- Wuchernde Struma Langhans
- Adenocarcinoma›Hurthle cell
- Adenocarcinoma›nonencapsulated sclerosing
- Carcinoma›Hurthle cell
- Carcinoma›nonencapsulated sclerosing
- Goiter›cancerous
- Goiter›malignant
- Hurthle cell›adenocarcinoma
- Hurthle cell›carcinoma
- Tumor›nonencapsulated sclerosing
- Adenocarcinoma›follicular›moderately differentiated
- Adenocarcinoma›follicular›trabecular
Code history
Unchanged in every release from FY2024 to FY2027.